Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On August 5, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update.</li><li> ESSA is currently studying its lead compound, masofaniten (EPI-7386), in two clinical trials: EPI-7386-CS-001 and EPI-7386-CS-010.</li><li>Full results from the monotherapy arm of the -001 trial will be presented at a scientific conference in the second half of 2024 while enrollment continues in the two combination arms.</li></ul>

On August 5, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update. ESSA is currently studying its lead compound, masofaniten (EPI-7386), in two clinical trials: EPI-7386-CS-001 and EPI-7386-CS-010.Full results from the monotherapy arm of the -001 trial will be presented at a scientific conference in the second half of 2024 while enrollment continues in the two combination arms.

EPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024 

<ul><li>On May 14, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and provided a business update.</li><li> ESSA is currently studying its lead compound, masofaniten (EPI-7386), in two clinical trials: EPI-7386-CS-001 and EPI-7386-CS-010.</li><li>The -001 trial consists of Part A monotherapy treatment and Part B combination therapy of masofaniten plus abiraterone acetate/prednisone (Cohort 1 mHSPC or mCRPC) or with apalutamide following 12 weeks of monotherapy therapy (Cohort 2 nmCRPC).</li></ul>

On May 14, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and provided a business update. ESSA is currently studying its lead compound, masofaniten (EPI-7386), in two clinical trials: EPI-7386-CS-001 and EPI-7386-CS-010.The -001 trial consists of Part A monotherapy treatment and Part B combination therapy of masofaniten plus abiraterone acetate/prednisone (Cohort 1 mHSPC or mCRPC) or with apalutamide following 12 weeks of monotherapy therapy (Cohort 2 nmCRPC).

EPIX: Updated Data from Phase 1 Trial of Masofaniten and Enzalutamide Expected in 2H24 

Canada

ESSA Pharma Inc., is a pharmaceutical company focused on the development of small molecule drugs for the treatment of prostate cancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Essa Pharma (EPIX US)

EPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024

On August 5, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and...

Zacks Small Cap Research

EPIX: Updated Data from Phase 1 Trial of Masofaniten and Enzalutamide Expected in 2H24

On May 14, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)